Landoni, Elisa
Woodcock, Mark G. http://orcid.org/0000-0001-7348-4980
Barragan, Gabriel
Casirati, Gabriele http://orcid.org/0000-0003-1925-1195
Cinella, Vincenzo http://orcid.org/0009-0002-8555-2906
Stucchi, Simone
Flick, Leah M.
Withers, Tracy A.
Hudson, Hanna
Casorati, Giulia http://orcid.org/0000-0002-5102-4112
Dellabona, Paolo http://orcid.org/0000-0002-1414-633X
Genovese, Pietro http://orcid.org/0000-0001-9507-9003
Savoldo, Barbara
Metelitsa, Leonid S.
Dotti, Gianpietro http://orcid.org/0000-0002-2639-8526
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA243543, P30CA016086, P30 DK034987)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | NIH Clinical Center (R01-CA262250)
Article History
Received: 28 July 2023
Accepted: 7 December 2023
First Online: 2 January 2024
Competing interests
: Dr. Dotti serves in the SAB of Catamaran Bio and Estella. Dr. Savoldo, Landoni and Dotti filed a patent for the technology developed in this manuscript (Title: Natural killer T-cells and methods of using the same. WO2023147564A3). No potential conflicts of interest were disclosed by the other authors in relation to this specific manuscript.